Results 141 to 150 of about 4,730,453 (227)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis

مجله دانشکده پزشکی اصفهان, 2017
Background: The aim of this study was to determine the efficacy of monthly cyclophosphamide and daily fingolimod in treatment of patients with multiple sclerosis (MS) and to compare these two treatment strategies.
Vahid Shaygannezhad, Hassan Amini
doaj  

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Cardiovascular-Cognitive Associations During Physiological Challenges in Relapsing-Remitting Multiple Sclerosis. [PDF]

Diseases
Racosta JM, Arocha-Perez J, Seo DH, Ayromlou S, Riccio PM.   +4 more
europepmc   +1 more source

Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

Transfusion, EarlyView.
Nabiha H. Saifee, Jennifer Andrews, Mary Berg, Stella T. Chou, Mischa Covington, Elizabeth P. Crowe, Ruchika Goel, Juliana A. Guarente, Tina Ipe, Jeremy W. Jacobs, Jessica Jacobson, Cyril Jacquot, Jenna Khan, Thane A. Kubik, Theodros Mamo, Michael F. Murphy, Kerry O'Brien, Monica B. Pagano, Anil K. Panigrahi, Jacqueline N. Poston, Scott E. Potter, Simon J. Stanworth, Moritz Stolla, Alyssa Ziman, Ryan A. Metcalf   +24 more
wiley   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, Volume 100, Issue 4, Page 808-823, October 2026.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Longitudinal Stability of the Gut Microbiota in Relapsing-Remitting Multiple Sclerosis: A Prospective Observational Study. [PDF]

Microorganisms
Vacaras C, Vacaras V, Nistor C, Jucan C, Furdui IM, Vesa SC, Strilciuc S, Ștefănescu E, Chira D, Rafila A, Muresanu DF.   +10 more
europepmc   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, Volume 100, Issue 4, Page 788-792, October 2026.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Over reliance on prior expectations in relapsing remitting multiple sclerosis. [PDF]

iScience
Pourmohammadi A, Rezaei H, Adibi A, Dehghani M, Gorji A, Sima S, Adibi I, Sanayei M.   +7 more
europepmc   +1 more source

Long Term Follow Up of Hereditary Thrombotic Thrombocytopenic Purpura on Plasma Therapy for 9 Years: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei, Chen Ruyue, Wu Shuang, Tang Hanyun, Lin Qiang, Li Xiaozhong   +5 more
wiley   +1 more source

Testosterone in Relapsing-Remitting Multiple Sclerosis: A Case-Control Study. [PDF]

J Clin Med
Rościszewska-Żukowska I, Popiel M, Perenc A, Rudnicka-Czerwiec J, Malska I, Bartosik-Psujek H.   +5 more
europepmc   +1 more source